Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Background

Diabetes mellitus (DM) is an autoimmune manifestation defined by persistent hyperglycemia and alterations in protein, fatty substances, and carbohydrate metabolism as an effect of problems with the secretion of insulin action or both. Manifestations include thirst, blurred eyesight, weight loss, and ketoacidosis, which can majorly lead to coma. There are different types of diabetes according to class or by cellular level. They are interrelated with hyperlipidemia as they are involved in the metabolism and regulation of physiological factors. Most parameters are seen at cellular or humoral levels, yet the underlying concern remains the same.

Objective

To create a systematic correlation between the disease and locate the exact mechanism and receptors responsible for it. So, this article covers a proper way to resolve the conditions and their manifestation through literacy and diagrammatic.

Conclusion

Hence, this will be an insight for many scholars to understand the exact mechanism involved in the process.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998289406240214093815
2024-02-23
2024-11-22

  • From This Site

    /content/journals/cdr/10.2174/0115733998289406240214093815
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WHO. Study group diabetes mellitus, Technical report series.World Health Organ. Tech. Rep. Ser.19857271113
     [Google Scholar]
  2. SinghN. KesherwaniR. TiwariA.K. PatelD.K. A review on diabetes mellitus.J. Pharm. Innov.2016573640 27717130
     [Google Scholar]
  3. KumarC.R. Basic Pathology, Prism PVT.5th edLimited Bangalore1992569587
     [Google Scholar]
  4. Ross and Wilson.Anatomy and pathophysiology in health and illness.11th edChurchill Livingstone Elsevier2010227229
     [Google Scholar]
  5. Global burden of disease collaborative network.2020Available from: https://vizhub.healthdata.org/gbd-results/
  6. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus.Diabetes Care19972071183119710.2337/diacare.20.7.1183 9203460
     [Google Scholar]
  7. American Diabetes Association. Diagnosis and classification of diabetes mellitus.Diabetes Care2014371S81S90 2435721510.2337/diacare.25.10.1862 12351492
     [Google Scholar]
  8. TobiasD.K. HuF.B. ChavarroJ. RosnerB. MozaffarianD. ZhangC. Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus.Arch. Intern. Med.2012172201566157210.1001/archinternmed.2012.3747 22987062
     [Google Scholar]
  9. KimC. NewtonK.M. KnoppR.H. Gestational diabetes and the incidence of type 2 diabetes: A systematic review.Diabetes Care2002251018621868
     [Google Scholar]
  10. American diabetes association. Standards of medical care in diabetes--2014.Diabetes Care201437S14S8010.2337/dc14‑S014 24357209
     [Google Scholar]
  11. LandonM.B. SpongC.Y. ThomE. A multicenter, randomized trial of treatment for mild gestational diabetes.N. Engl. J. Med.2009361141339134810.1056/NEJMoa0902430 19797280
     [Google Scholar]
  12. CrowtherC.A. HillerJ.E. MossJ.R. McPheeA.J. JeffriesW.S. RobinsonJ.S. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.N. Engl. J. Med.2005352242477248610.1056/NEJMoa042973 15951574
     [Google Scholar]
  13. VandorstenJ.P. DodsonW.C. EspelandM.A. NIH consensus development conference: Diagnosing gestational diabetes mellitus.NIH Consens. State Sci. Statements2013291131 23748438
     [Google Scholar]
  14. KahnC.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes.Diabetes19944381066108510.2337/diab.43.8.1066 8039601
     [Google Scholar]
  15. HorvathK KochK JeitlerK Effects of treatment in women with gestational diabetes mellitus: Systematic review and metaanalysis.BMJ 2010340apr01 1c139510.1136/bmj.c1395 20360215
     [Google Scholar]
  16. WeyerC. BogardusC. MottD.M. PratleyR.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.J. Clin. Invest.1999104678779410.1172/JCI7231 10491414
     [Google Scholar]
  17. SurampudiP.N. John-KalarickalJ. FonsecaV.A. Emerging concepts in the pathophysiology of type 2 diabetes mellitus.Mt. Sinai J. Med.200976321622610.1002/msj.20113 19421965
     [Google Scholar]
  18. OlokobaA.B. ObateruO.A. OlokobaL.B. Type 2 diabetes mellitus: A review of current trends.Oman Med. J.201227426927310.5001/omj.2012.68 23071876
     [Google Scholar]
  19. ZimmetP. AlbertiK.G.M.M. ShawJ. Global and societal implications of the diabetes epidemic.Nature2001414686578278710.1038/414782a 11742409
     [Google Scholar]
  20. WildS. RoglicG. GreenA. SicreeR. KingH. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030.Diabetes Care20042751047105310.2337/diacare.27.5.1047 15111519
     [Google Scholar]
  21. DeshmukhC.D. Diabetes mellitus: A review.IJPAB201533224230
     [Google Scholar]
  22. BergmanR.N. SteilG.M. BradleyD.C. WatanabeR.M. Modeling of insulin action in vivo.Annu. Rev. Physiol.199254186188310.1146/annurev.ph.54.030192.004241 1562195
     [Google Scholar]
  23. RobertsonR.P. Antagonist: Diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis.J. Lab. Clin. Med.19951255560564 7738421
     [Google Scholar]
  24. RangH.P. DaleM.M. Pharmacology, sixth edition, churchill livingstone.In: The Endocrine Pancreas and Control of Blood Glucose.Churchill Livingstone2008397409
     [Google Scholar]
  25. Sims-RobinsonC. KimB. RoskoA. FeldmanE.L. How does diabetes accelerate Alzheimer disease pathology?Nat. Rev. Neurol.201061055155910.1038/nrneurol.2010.130 20842183
     [Google Scholar]
  26. VermaS GuptaM PopliH AggarwalG Diabetes mellitus treatment using herbal drugs.Int J Phytomed20181010110.5138/09750185.2181
     [Google Scholar]
  27. TabatabaeimalazyO. Targeting metabolic disorders by natural products.J. Diabetes Metab. Disord.20151457
     [Google Scholar]
  28. AbutalebM.H. Diabetes Mellitus: An overview.Pharm. Pharmacol. Int. J.20164540641110.15406/ppij.2016.04.00087
     [Google Scholar]
  29. JoshiS.K. ShresthaS. Diabetes mellitus: A review of its associations with different environmental factors.Kathmandu Univ. Med. J.2010829109115[KUMJ.21209519
     [Google Scholar]
  30. MohanV. PradeepaR. Epidemiology of diabetes in different regions of India.Indian J. Ophthalmol.2009691129322938
     [Google Scholar]
  31. Diagnosis and classification of diabetes mellitus.Diabetes Care201235Suppl. 1S64S71 22187472
     [Google Scholar]
  32. American diabetes association. Standards of medical care in diabetes--2008.Diabetes Care200831S12S5410.2337/dc08‑S012 18165335
     [Google Scholar]
  33. SchlichtmannJ. GraberM.A. Hematologic, electrolyte, and metabolic disorders.The Family Practice Handbook.3rd ed GraberM.A. TothP.P. HertingR.L. St. Louis, MissouriMosby-Year Book Inc.1997192251
     [Google Scholar]
  34. WingR.R. KoeskeR. EpsteinL.H. NowalkM.P. GoodingW. BeckerD. Long-term effects of modest weight loss in type II diabetic patients.Arch. Intern. Med.1987147101749175310.1001/archinte.1987.00370100063012 3310940
     [Google Scholar]
  35. KartonoA. IrawatiF.D. SetiawanA.A. SyafutraH. SumaryadaT. The effects of physical exercise on the insulin-dependent diabetes mellitus subjects using the modified minimal model.Int. J. Pharm. Pharm. Sci.20179217910.22159/ijpps.2017v9i2.15621
     [Google Scholar]
  36. American diabetes association. Clinical practice recommendations 1995. Position statement: Diabetes mellitus and exercise.Diabetes Care1995182810.2337/diacare.18.1.S28
     [Google Scholar]
  37. ThangasamiS.R. ChandaniA.L. ThangasamiS. Emphasis of yoga in the management of diabetes.J. Diabetes Metab.2015610210.4172/2155‑6156.1000613
     [Google Scholar]
  38. DeFronzoR.A. Pharmacologic therapy for type 2 diabetes mellitus.Ann. Intern. Med.1999131428130310.7326/0003‑4819‑131‑4‑199908170‑00008 10454950
     [Google Scholar]
  39. NissenS.E. WolskiK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N. Engl. J. Med.2007356242457247110.1056/NEJMoa072761 17517853
     [Google Scholar]
  40. CryerP.E. DavisS.N. ShamoonH. Hypoglycemia in diabetes.Diabetes Care20032661902191210.2337/diacare.26.6.1902 12766131
     [Google Scholar]
  41. KorytkowskiM. When oral agents fail: Practical barriers to starting insulin.Int. J. Obes.200226S3S18S2410.1038/sj.ijo.0802173 12174319
     [Google Scholar]
  42. HoP.M. RumsfeldJ.S. MasoudiF.A. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.Arch. Intern. Med.2006166171836184110.1001/archinte.166.17.1836 17000939
     [Google Scholar]
  43. SvenssonM. ErikssonJ.W. DahlquistG. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: A population-based study in northern Sweden.Diabetes Care2004274955962
     [Google Scholar]
  44. RathodS. AkshayJ. RodeA. ShravanS. A review on diabetics.Int. Multidiscip. Res. J.20235311310.2337/diacare.27.4.955 15047655
     [Google Scholar]
  45. MumthajP. NatarajanP. JananiA.M. A global review article on hyperlipidemia.IJPSRR2021681104110
     [Google Scholar]
  46. MishraPR PandaPK ApannaKC PanigrahiS Evaluation of acute hypolipidemic activity of different plant extracts in Triton WR-1339 induced pharmacologyonline.hyperlipidemia 2011392534
     [Google Scholar]
  47. DiPiroJ.T. WellsB.G. SchwinghammerT.L. DiPiroC.V. Pharmacotherapy handbook.Appleton & Lange2000
     [Google Scholar]
  48. ChaitA. BrunzellJ.D. Acquired hyperlipidemia (secondary dyslipoproteinemias).Endocrinol. Metab. Clin. North Am.199019225927810.1016/S0889‑8529(18)30324‑4 2192873
     [Google Scholar]
  49. GoodmanL.S. GilmanA. The pharmacological basis of therapeutics.New YorkMacmillan1970
     [Google Scholar]
  50. HassanB. Overview on hyperlipidemia.J Chromat Separation Techniq2013421
     [Google Scholar]
  51. VijayarajP.S. MuthukumarK. SabarirajanJ. NaciappanV. IJBB2011485458
     [Google Scholar]
  52. KalioraA.C. DedoussisG.V.Z. SchmidtH. Dietary antioxidants in preventing atherogenesis.Atherosclerosis2006187111710.1016/j.atherosclerosis.2005.11.001 16313912
     [Google Scholar]
  53. DhuleyJ.N. NaikS.R. ReleS. BanerjiA. Hypolipidaemic and antioxidant activity of diallyl disulphide in rats.Pharm. Pharmacol. Commun.199951268969610.1211/146080899128734406
     [Google Scholar]
  54. ShetgiriP.P. D’MelloP.M. Indian Drugs200340567569
     [Google Scholar]
  55. GopinathanN. SrinivasanK.K. MathewJ.E. Indian Drugs200441633635
     [Google Scholar]
  56. RajaniG.P. AshokP. In vitro antioxidant and antihyperlipidemic activities of Bauhinia variegata Linn.Indian J. Pharmacol.200941522723210.4103/0253‑7613.58513 20177495
     [Google Scholar]
  57. SinghR. NainS. A mini review on hyperlipidemia: Common clinical problem.J. Interv. Cardiol.20181013
     [Google Scholar]
  58. RanadiveG.N. LalaA.K. Sterol-phospholipid interaction in model membranes: Role of C5-C6 double bond in cholesterol.Biochemistry19872692426243110.1021/bi00383a005 3607024
     [Google Scholar]
  59. HainesT.H. Do sterols reduce proton and sodium leaks through lipid bilayers?Prog. Lipid Res.200140429932410.1016/S0163‑7827(01)00009‑1 11412894
     [Google Scholar]
  60. EsfahaniM. ScerboL. DevlinT.M. A requirement for cholesterol and its structural features for a human macrophage‐like cell line.J. Cell. Biochem.1984252879710.1002/jcb.240250204 6480716
     [Google Scholar]
  61. VanceD. Van den BoschH. Cholesterol in the year 2000.Biochim. Biophys. Acta Mol. Cell Biol. Lipids200015291-31810.1016/S1388‑1981(00)00133‑5 11111073
     [Google Scholar]
  62. YeagleP.L. Cholesterol and the cell membrane.Biochim. Biophys. Acta Rev. Biomembr.19858223-426728710.1016/0304‑4157(85)90011‑5 3904832
     [Google Scholar]
  63. MiaoL. NielsenM. ThewaltJ. From lanosterol to cholesterol: Structural evolution and differential effects on lipid bilayers.Biophys. J.20028231429144410.1016/S0006‑3495(02)75497‑0 11867458
     [Google Scholar]
  64. AwadA.B. FinkC.S. Phytosterols as anticancer dietary components: Evidence and mechanism of action.J. Nutr.200013092127213010.1093/jn/130.9.2127 10958802
     [Google Scholar]
  65. BergeK.E. TianH. GrafG.A. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.Science200029054971771177510.1126/science.290.5497.1771 11099417
     [Google Scholar]
  66. SimonsK. EhehaltR. Cholesterol, lipid rafts, and disease.J. Clin. Invest.2002110559760310.1172/JCI0216390 12208858
     [Google Scholar]
  67. PriorI.A. HancockJ.F. Compartmentalization of Ras proteins.J. Cell Sci.200111491603160810.1242/jcs.114.9.1603 11309191
     [Google Scholar]
  68. SundaramM. YaoZ. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.Nutr. Metab.2010713510.1186/1743‑7075‑7‑35 20423497
     [Google Scholar]
  69. RidkerP.M. GenestJ. BoekholdtS.M. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial.Lancet2010376973833333910.1016/S0140‑6736(10)60713‑1 20655105
     [Google Scholar]
  70. MozaffarianD. BenjaminE.J. GoA.S. Heart disease and stroke statistics—2016 update: A report from the American Heart Association.Circulation20161334e38e36010.1161/CIR.0000000000000350 26673558
     [Google Scholar]
  71. Centers for disease control and prevention (CDC). Vital signs: Prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200.MMWR Morb. Mortal. Wkly. Rep.2011604109114 21293326
     [Google Scholar]
  72. KarrS. Epidemiology and management of hyperlipidemia.AJMC2017239S139S148 28978219
     [Google Scholar]
  73. SimonsM. KellerP. DichgansJ. SchulzJ.B. Cholesterol and Alzheimer’s disease.Neurology20015761089109310.1212/WNL.57.6.1089 11571339
     [Google Scholar]
  74. GuptaR. MohanI. NarulaJ. Trends in coronary heart disease epidemiology in India.Ann. Glob. Health201682230731510.1016/j.aogh.2016.04.002 27372534
     [Google Scholar]
  75. KeaneW.F. St PeterJ.V. KasiskeB.L. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?Kidney Int. Suppl.199238S134S141 1405364
     [Google Scholar]
  76. NelsonR.H. Hyperlipidemia as a risk factor for cardiovascular disease.Prim. Care201340119521110.1016/j.pop.2012.11.003 23402469
     [Google Scholar]
  77. PetterssonC. Studies on the atherogenicity of Apo B containing lipoproteins in type 2 diabetes Institute of Medicine.Department of Molecular and Clinical Medicine2009
     [Google Scholar]
  78. StoneN.J. RobinsonJ.G. LichtensteinA.H. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines.J. Am. Coll. Cardiol.201463252889293410.1016/j.jacc.2013.11.002 24239923
     [Google Scholar]
  79. OgdenC.L. CarrollM.D. KitB.K. FlegalK.M. Prevalence of childhood and adult obesity in the United States, 2011-2012.JAMA2014311880681410.1001/jama.2014.732 24570244
     [Google Scholar]
  80. ACC/AHA ACC/AHA. ACC/AHA ASCVD Risk Calculator website.2016Available from: www.cvriskcalculator.com(Accessed May 23, 2017).
  81. ItoM.K. WattsG.F. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia.Drugs201575151715172410.1007/s40265‑015‑0466‑y 26370207
     [Google Scholar]
  82. SjoukeB. KustersD.M. KindtI. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype–phenotype relationship, and clinical outcome.Eur. Heart J.201536956056510.1093/eurheartj/ehu058 24585268
     [Google Scholar]
  83. NordestgaardB.G. ChapmanM.J. HumphriesS.E. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society.Eur. Heart J.201334453478349010.1093/eurheartj/eht273 23956253
     [Google Scholar]
  84. KheraA.V. WonH.H. PelosoG.M. Diagnostic yield and clinical utility of sequencing famil ial hypercholesterolemia genes in patients with severe hypercholesterolemia.J. Am. Coll. Cardiol.201667222578258910.1016/j.jacc.2016.03.520 27050191
     [Google Scholar]
  85. NaserI.H. AlkareemZ.A. MosaA.U. Hyperlipidemia: Pathophysiology, causes, complications and treatment, A Review.J. Pharm. Pharm. Sci.2021118132
     [Google Scholar]
  86. HillM.F. BordoniB. Hyperlipidemia. In: StatPearls.Treasure Island, FLStatPearls Publishing2023
     [Google Scholar]
  87. EdeogaH.O. OkwuD.E. MbaebieB.O. Phytochemical constituents of some Nigerian medicinal plants.AJB2005197685688
     [Google Scholar]
  88. CunninghamA.B. An investigation of the herbal medicine trade in Natal/KwaZulu.Institute of Natural Resources, University of Natal1988
     [Google Scholar]
  89. VermaN. Introduction to hyperlipidemia and its treatment: A review.Int. J. Curr. Pharm. Res.20169161410.22159/ijcpr.2017v9i1.16616
     [Google Scholar]
  90. BelayB. BelamarichP.F. Tom-RevzonC. The use of statins in pediatrics: Knowledge base, limitations, and future directions.Pediatrics2007119237038010.1542/peds.2006‑0787 17272627
     [Google Scholar]
  91. BersotT.P. Drug therapy for hypercholesterolemia and dyslipidemia Goodman and Gilman’s, The Pharmacological Basis of Therapeutics.McGraw-Hill2011877908
     [Google Scholar]
  92. RussellD.W. The enzymes, regulation, and genetics of bile acid synthesis.Annu. Rev. Biochem.200372113717410.1146/annurev.biochem.72.121801.161712 12543708
     [Google Scholar]
  93. SafeerR.S. LacivitaC.L. Choosing drug therapy for patients with hyperlipidemia.Am. Fam. Physician2000611133713382 10865931
     [Google Scholar]
  94. HarikumarK. NivedithaB. ReddyP.K. Int J Phytopharm201233256262
     [Google Scholar]
  95. AhmedS.M. ClasenM.D. DonnellyM.D. Managment of dyslipidemia in adults.Am. Fam. Physician199857116
     [Google Scholar]
  96. DieboldB.A. BhagavanN.V. GuilloryR.J. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs.Biochim. Biophys. Acta, Gen. Subj.19941200210010810.1016/0304‑4165(94)90123‑6 8031828
     [Google Scholar]
  97. NiroshaK. DivyaM. VamsiS. MohemmedS. A review on hyperlipidemia.Int. J. Novel Trends Pharm. Sci.2014458192
     [Google Scholar]
  98. OnweP.E. FolawiyoM.A. Anyigor-OgahC.S. UmahiG. OkorochaA.E. AfokeA.O. J. Med. Dent. Sci.2015141093100
     [Google Scholar]
  99. YuanG. KhalidZ. Hypertriglyceridemia: Its etiology, effects and treatment.Can Med Assoc200717681113112010.1503/cmaj.060963
     [Google Scholar]
  100. RubinsH.B. RobinsS.J. CollinsD. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).Arch. Intern. Med.2002162222597260410.1001/archinte.162.22.2597 12456232
     [Google Scholar]
  101. Bhatt.Int. J. Physiol. Pathophysiol. Pharmacol.2010215763 21383898
     [Google Scholar]
  102. CannerP.L. BergeK.G. WengerN.K. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin.J. Am. Coll. Cardiol.1986861245125510.1016/S0735‑1097(86)80293‑5 3782631
     [Google Scholar]
  103. CarlsonL.A. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug.Int. J. Clin. Pract.200458770671310.1111/j.1368‑5031.2004.00233.x 15311728
     [Google Scholar]
  104. BélichardP. PruneauD. ZhiriA. Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster.Biochim. Biophys. Acta Lipids Lipid Metab.1993116919810210.1016/0005‑2760(93)90087‑P 8334156
     [Google Scholar]
  105. McKenneyJ.M. FarnierM. LoK.W. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.J. Am. Coll. Cardiol.20064781584158710.1016/j.jacc.2005.11.072 16630994
     [Google Scholar]
  106. GoldbergI.J. Clinical review 124: Diabetic dyslipidemia: Causes and consequences.J. Clin. Endocrinol. Metab.200186396597110.1210/jcem.86.3.7304 11238470
     [Google Scholar]
  107. GinsbergH.N. Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels.Diabetes199645S27S3010.2337/diab.45.3.S27 8674885
     [Google Scholar]
  108. KraussR.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk.Curr. Opin. Lipidol.19945533934910.1097/00041433‑199410000‑00005 7858908
     [Google Scholar]
  109. HaffnerS.M. MykkänenL. FestaA. BurkeJ.P. SternM.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state.Circulation2000101997598010.1161/01.CIR.101.9.975 10704163
     [Google Scholar]
  110. DixonJ.L. FurukawaS. GinsbergH.N. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B.J. Biol. Chem.199126685080508610.1016/S0021‑9258(19)67758‑6 1848237
     [Google Scholar]
  111. TaghibiglouC. CarpentierA. Van IderstineS.C. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model.J. Biol. Chem.2000275128416842510.1074/jbc.275.12.8416 10722675
     [Google Scholar]
  112. De ManF.H.A.F. Castro CabezasM. Van BarlingenH.H.J.J. ErkelensD.W. De BruinT.W.A. Triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetes mellitus: post‐prandial metabolism and relation to premature atherosclerosis.Eur. J. Clin. Invest.19962628910810.1046/j.1365‑2362.1996.114256.x 8904518
     [Google Scholar]
  113. LewisG.F. O’MearaN.M. SoltysP.A. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities.J. Clin. Endocrinol. Metab.199172493494410.1210/jcem‑72‑4‑934 2005221
     [Google Scholar]
  114. LewisG.F. O’MearaN.M. CabanaV.G. Postprandial triglyceride response in Type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacement.Diabetologia199134425325910.1007/BF00405084 2065859
     [Google Scholar]
  115. EbaraT. CondeK. KakoY. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.J. Clin. Invest.2000105121807181810.1172/JCI8283 10862796
     [Google Scholar]
  116. FebbraioM. AbumradN.A. HajjarD.P. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism.J. Biol. Chem.199927427190551906210.1074/jbc.274.27.19055 10383407
     [Google Scholar]
  117. IshidaB.Y. BlancheP.J. NicholsA.V. YasharM. PaigenB. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H.J. Lipid Res.199132455956810.1016/S0022‑2275(20)42043‑7 1856605
     [Google Scholar]
  118. VéniantM.M. PierottiV. NewlandD. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.J. Clin. Invest.1997100118018810.1172/JCI119511 9202070
     [Google Scholar]
  119. GoldbergI.J. LeN.A. GinsbergH.N. KraussR.M. LindgrenF.T. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.J. Clin. Invest.198881256156810.1172/JCI113354 3276735
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998289406240214093815
Loading
Effects of Diabetes and Hyperlipidemia in Physiological Conditions - A Review
Curr. Diabetes Rev. 21, E230224227362 (2025); https://doi.org/10.2174/0115733998289406240214093815
/content/journals/cdr/10.2174/0115733998289406240214093815
/content/journals/cdr/10.2174/0115733998289406240214093815
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): autoimmune; Diabetes; hyperglycemia; hyperlipidemia; insulin secretion; ketoacidosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test